IN8BIO, INC. Files 8-K Report
Ticker: INAB · Form: 8-K · Filed: Feb 11, 2025 · CIK: 1740279
| Field | Detail |
|---|---|
| Company | In8bio, Inc. (INAB) |
| Form Type | 8-K |
| Filed Date | Feb 11, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-k, financials, corporate-filing
TL;DR
IN8BIO filed a routine 8-K, no major news.
AI Summary
On February 11, 2025, IN8bio, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, indicating routine corporate activity rather than a specific event. The company, previously known as Incysus Therapeutics, Inc., is incorporated in Delaware and headquartered in New York.
Why It Matters
This 8-K filing indicates routine corporate disclosures, suggesting no immediate material event has occurred that requires public announcement beyond standard financial reporting.
Risk Assessment
Risk Level: low — The filing is a standard 8-K for financial statements and exhibits, not indicating any significant new risks or events.
Key Numbers
- 001-39692 — SEC File Number (Identifies the company's filing with the SEC.)
- 82-5462585 — IRS Employer Identification No. (Company's tax identification number.)
Key Players & Entities
- IN8BIO, INC. (company) — Registrant
- Incysus Therapeutics, Inc. (company) — Former Company Name
- February 11, 2025 (date) — Date of Report
- Delaware (jurisdiction) — State of Incorporation
- New York (location) — Principal Executive Offices City
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report financial statements and exhibits, as indicated by the 'ITEM INFORMATION' section.
When was this report filed?
This report was filed on February 11, 2025.
What was IN8BIO, Inc.'s former name?
IN8BIO, Inc.'s former name was Incysus Therapeutics, Inc.
In which state is IN8BIO, Inc. incorporated?
IN8BIO, Inc. is incorporated in Delaware.
What is the address of IN8BIO, Inc.'s principal executive offices?
The address of IN8BIO, Inc.'s principal executive offices is 350 5th Avenue, Suite 5330, New York, New York 10118.
Filing Stats: 474 words · 2 min read · ~2 pages · Grade level 10.8 · Accepted 2025-02-11 08:11:58
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value per share INAB The Nasdaq
Filing Documents
- d905966d8k.htm (8-K) — 25KB
- d905966dex991.htm (EX-99.1) — 27KB
- g905966g0211031542881.jpg (GRAPHIC) — 2KB
- 0001193125-25-024005.txt ( ) — 186KB
- inab-20250211.xsd (EX-101.SCH) — 3KB
- inab-20250211_lab.xml (EX-101.LAB) — 18KB
- inab-20250211_pre.xml (EX-101.PRE) — 11KB
- d905966d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits . Exhibit No. Description 99.1 Press Release, dated February 11, 2025. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. IN8bio, Inc. Dated: February 11, 2025 By: /s/ Patrick McCall Patrick McCall Chief Financial Officer and Secretary (Principal Financial and Accounting Officer)